Drugs / CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes
CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01740557 | Jan 2015 → Apr 2023 | cutaneous melanoma, metastatic melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01740557 ↗ |
| Modality | Cell therapy | “genetically modified therapeutic autologous lymphocytes (patient's own white blood cells)” NCT01740557 ↗ |
| Route | Intravenous | “Given IV” NCT01740557 ↗ |